2016 Statements and Testimony

December 13, 2016 - Listening Session with the FDA Commissioner
Janet Shoemaker and Kimberly Walker from ASM participated in a listening session with FDA Commissioner Robert Califf on rare diseases.

December 2, 2016 - 21st Century Cures Bill Passes House
The 21st Century Cures Act passed the House of Representatives on November 30.  It authorizes $4.8 billion over a ten year period for targeted initiatives at the NIH and $500 million for the FDA.  The bill is expected to be voted on in the Senate the week of December 5.  The Office of Public Affairs has prepared an analysis of the bill's provisions.

November 11, 2016 - ASM and PASCV Comment on Transplant Virus Testing
The ASM and Pan American Society for Clinical Virology (PASCV)  comment on reclassification of tests for the measurement of virus DNA levels in transplant-associated infections.

November 9, 2016 - ASM Recommendations to the Presidential Transition
The ASM sent policy recommendations to strengthen science, technology and public health in the United States to President-elect Donald Trump transition advisors.

November 2, 2016 - ASM Signs on to Letter Regarding the 21st Century Cures Bill
The ASM joined more than 200 organizations in sending a letter to Speaker Ryan, Leader McCarthy, Leader Pelosi, Leader McConnell and Leader Reid urging them to include $34.1 billion for NIH in the FY 2017 spending bill.

October 26, 2016 - ASM Joins PEW, IDSA and BD in Breakpoints Letter to Senate HELP Committee        
ASM, PEW, IDSA and BD sent a letter to Senate HELP Committee Chairman Alexander and Ranking Member Murray asking them to consider language to streamline the process for updating breakpoints as they work to finalize the21st Century Cures innovation legislation. 

October 17, 2016 - ASM, AMP and PASCV Express Concerns On New Molecular Test for Zika
The ASM, the Association for Molecular Pathology (AMP) and Pan American Society for Clinical Virology (PASCV) ask for data and clarification on the  rRT-PCR assay for the testing of Zika, dengue and chikungunya viruses.

September 29, 2016 - ASM Participates in FDA AST Public Workshop
Melissa Miller, Chair of the Laboratory Practices Committee represented ASM in the Coordinated Development of Antimicrobial Drugs and Antimicrobial Susceptibility Test Devices public workshop. Information about the workshop is available here.

September 13, 2016 - ASM, AMP, APHL, IDSA and PASCV Comment  on NGS Diagnostics
ASM joined several societies to submit written comments on the FDA draft guidance entitled “Infectious Disease Next Generation Sequencing Based Diagnostic Devices: Microbial Identification and Detection of Antimicrobial Resistance and Virulence Markers."

September 7, 2016 - ASM Signs Letter to Congressional Leadership Regarding FY 2017 Funding for Research Funding
The ASM joined 210 other organization in a letter to congress urging inclusion of the Senate proposed $34.1 billion for the National Institutes of Health (NIH) in a final fiscal year (FY) 2017 spending package.

August 30, 2016 - ASM Asks for Clarification on CLIA Personnel Regulations
ASM requests clarification on an April CMS State Survey Agency Directors memorandum regarding personnel policies on individuals performing non-waived tests.

August 29, 2016 - ASM Letter Concerning UN Meeting on Antimicrobial Resistance
ASM sent a letter Samantha Power, the US Ambassador to the United Nations regarding the September 21 meeting of the UN General Assembly on antimicrobial resistance

July 27, 2016 - ASM Asks VA for Clarification on Proposed Advance Practice Registered Nurse Duty Changes
ASM comments focus on Advance Practice Nurses ability to perform laboratory

July 18, 2016 - ASM Urges Congressional Action on Emergency Zika Funding
The ASM sent Majority Leader McConnell and Minority Leader Reid, Speaker Ryan and Minority Leader Pelosi a letter urging action on funding to combat the threat of Zika.

July 13, 2016 - Payment Determinations for Calendar Year 2017 for New Clinical Laboratory Tests
The ASM presented recommendations to the Centers for Medicare & Medicaid Services (CMS) at its annual Clinical Laboratory Fee Schedule public meeting determining payment levels for new tests for 2017.

July 6, 2016 - Statement on the American Innovation and Competitiveness Act
The ASM signed onto a statement from the Coalition for National Science Funding to the Senate thanking them for introducing the American Innovation and Competitiveness Act (S. 3084) which would provide funding for the NSF. 

June 29, 2016 - ASM Meets with OSTP’s Fast Track Action Committee on Biosafety
The FTAC was tasked with gathering information on two issues:  whether to bring all bioscience institutions, or at least all these operating at or above Biosafety Level 3, or high containment, under federal biosafety regulation and the feasibility of adopting a “risk-based” approach to managing the safety and security oversight of biological agents and toxins.

June 10, 2016 - ASM Thanks Senate Subcommittee for NIH $2 Billion Budget Increase
The ASM sent letters to Senators Roy Blunt and Patty Murray thanking the Senate Labor/HHS Subcommittee for proposing a $2 Billion budget increase for the National Institutes of Health.

June 7, 2016 - ASM Supports Antibiotic Incentive Amendment to the National Defense Authorization Act (NDAA)
The ASM has signed a letter supporting an amendment on antibiotic development to the NDAA which would facilitate development of antibiotics to treat serious infections.  To read a fact sheet on the antibiotic amendment click here.

May 26, 2016 - ASM and APHL Make Recommendations on the  Biosafety in Microbiological and Biomedical Laboratories (BMBL) 5th Edition
The ASM and and the Association of Public Health Laboratories jointly authored recommendations on the upcoming edition of Biosafety in Microbiological and Biomedical Laboratories (BMBL), which include the need for more clinical and public health representation in the document. 

May 24, 2016 - ASM Letter on DOE FY 2017 Appropriations
The ASM sent a letter to all members of the House of Representatives regarding DOE Provisions in House Amendment to S. 2012, the Energy Policy Modernization Act of 2016.

May 18, 2016 - ASM Supports $1.9 Billion Emergency Funding to Combat Zika
The ASM sent a letter to Congress supporting the full $1.9 emergency funding request to combat Zika.

May 11, 2016 - ASM Comments on Department of Labor Employee Exemptions Definitions Impact on Research
The ASM sent a letter to Howard A. Shelanski, Ph.D., Administrator, Office of Information and Regulatory Affairs, Office of Management and Budget regarding the impact of the Department of Labor’s “Defining and Delimiting the Exemptions for Executive, Administrative, Professional, Outside Sales and Computer Employees” on research. 

May 3, 2016 - ASM Acts to Counter Zika Virus Outbreak

April 27, 2016 - ASM Joins IDSA and PASCV in Letter to FDA Commissioner on LDT Regulation
ASM, the Infectious Disease Society of America (IDSA) and the Pan-American Society for Clinical Virology (PASCV) sent a joint letter to FDA Commissioner Robert Califf detailing concerns about regulation of laboratory developed tests (LDTs) used for infectious disease evaluation.

April 26, 2016 - ASM Members Meet with Senate Appropriations Chair
ASM volunteer leaders met with Senator Thad Cochran (R-MS), Chair of the Senate Committee on Appropriations and participated in the 22nd Annual Coalition for National Science Funding (CNSF) Capitol Hill Exhibition and Reception.

April 8, 2016 - ASM Letter on Zika and Emerging Infectious Disease Funding
The ASM sent a letter to Congress regarding emergency funding for the Zika outbreak.  The ASM supports providing new funding to fight public health emergencies.

March 23, 2016 - ASM Endorses Letter on Preparedness Funding
The ASM signed onto a letter urging Congress to support funding for programs critical to the nation’s preparedness against emerging infectious disease threats.

March 23, 2016 - ASM Endorses Letter on Antimicrobial Funding
The ASM signed onto a letter asking Congress to support increased funding for antimicrobial resistance programs in the Fiscal Year (FY) 2017 appropriations process.

March 14, 2016 - ASM Comments on Select Agents and Toxins Regulations
The ASM sent comments to the Centers for Disease Control and Prevention (CDC) and the Animal and Plant Health Inspection Service (APHIS) regarding the biennial review of the List of Select Agents and Toxins and enhanced biosafety requirements.

March 11, 2017 - ASM Funding Recommendations to Congress for Fiscal Year 2017 

The ASM has submitted appropriation recommendations for federal agencies that support biomedical and public health research. 

February 23, 2016 - ASM Endorses Letter Requesting Additional Funding for Zika
The ASM signed onto a letter sent to Congress supporting the White House request for supplemental funds to prepare for and respond to Zika.

February 19, 2016 - ASM Letter Supports Increased AFRI Funding
The ASM sent a letter to Congress supporting a funding level of $700 million in the FY 2017 budget for the U.S. Department of Agriculture’s Agriculture and Food Research Initiative (AFRI). 

February 12, 2016 - ASM Letter to Congress Regarding Zika Virus
The ASM sent a letter to Congress supporting the President's supplemental budget request of $1.8 billion to prepare and respond to the Zika virus outbreak. 

February 11, 2016 - ASM Advisory to Members on the President’s FY 2017 Budget Request for Science and Public Health
The ASM Office of Public Affairs has prepared a summary of the Administration's FY 2017 budget request to Congress.  This summary includes special funding to combat the spread of the Zika virus.